Follow
Stanley T Crooke
Stanley T Crooke
Chairman and CEO Ionis pharmaceuticals
Verified email at ionisph.com - Homepage
Title
Cited by
Cited by
Year
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised …
FJ Raal, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, ...
The Lancet 375 (9719), 998-1006, 2010
10292010
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents: a comparative analysis
TA Vickers, S Koo, CF Bennett, ST Crooke, NM Dean, BF Baker
Journal of Biological Chemistry 278 (9), 7108-7118, 2003
7782003
Progress in antisense technology
ST Crooke
Annu. Rev. Med. 55, 61-95, 2004
7082004
Antisense oligonucleotides targeting apolipoprotein (a) in people with raised lipoprotein (a): two randomised, double-blind, placebo-controlled, dose-ranging trials
NJ Viney, JC van Capelleveen, RS Geary, S Xia, JA Tami, ZY Rosie, ...
The Lancet 388 (10057), 2239-2253, 2016
7012016
Oligoribonucleotides and ribonucleases for cleaving RNA
ST Crooke
US Patent 6,107,094, 2000
6832000
RNA-targeted therapeutics
ST Crooke, JL Witztum, CF Bennett, BF Baker
Cell metabolism 27 (4), 714-739, 2018
6532018
Mitomycin C: a review
ST Crooke, WT Bradner
Cancer treatment reviews 3 (3), 121-139, 1976
6221976
Molecular mechanisms of action of antisense drugs
ST Crooke
Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1489 (1 …, 1999
6111999
Antisense drug technology: principles, strategies, and applications
ST Crooke
CRC press, 2007
6072007
Therapeutic applications of oligonucleotides
ST Crooke
Annual review of pharmacology and toxicology 32 (1), 329-376, 1992
6061992
Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
FH Drake, GA Hofmann, HF Bartus, MR Mattern, ST Crooke, CK Mirabelli
Biochemistry 28 (20), 8154-8160, 1989
5991989
Oligoribonucleotides for cleaving RNA
ST Crooke
US Patent 5,898,031, 1999
5911999
Cisplatin (cis-diamminedichloroplatinum II)
AW Prestayko, JC D'aoust, BF Issell, ST Crooke
Cancer treatment reviews 6 (1), 17-39, 1979
5621979
Antisense research and applications
ST Crooke, B Lebleu
CRC Press, 1993
5171993
Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant
D Finley, S Sadis, BP Monia, P Boucher, DJ Ecker, ST Crooke, V Chau
Molecular and cellular biology 14 (8), 5501-5509, 1994
4991994
Progress in antisense oligonucleotide therapeutics
ST Crooke, CF Bennett
Annual Review of Pharmacology and Toxicology 36 (1), 107-129, 1996
4791996
Cellular uptake and trafficking of antisense oligonucleotides
ST Crooke, S Wang, TA Vickers, W Shen, X Liang
Nature biotechnology 35 (3), 230-237, 2017
4772017
Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
ST Crooke, MJ Graham, JE Zuckerman, D Brooks, BS Conklin, ...
Journal of Pharmacology and Experimental Therapeutics 277 (2), 923-937, 1996
4181996
Evaluation of the in Vivo Antitumor Activity and in Vitro Cytotoxic Properties of Auranofin, a Coordinated Gold Compound, in Murine Tumor Models
CK Mirabelli, RK Johnson, CM Sung, L Faucette, K Muirhead, ST Crooke
Cancer research 45 (1), 32-39, 1985
4131985
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
MJ Graham, KM Lemonidis, CP Whipple, A Subramaniam, BP Monia, ...
Journal of lipid research 48 (4), 763-767, 2007
4112007
The system can't perform the operation now. Try again later.
Articles 1–20